Study Summary
This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Want to learn more about this trial?
Request More InfoInterventions
CARCIK-CD19BIOLOGICAL
Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ospedale PG23 | Bergamo | BG | Italy |
| Fondazione MBBM | Monza | MB | Italy |